Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized CBT vs Antidepressants in MDD/PDD (CANBIND6)
NCT02752542Phase 4Recruiting
- Sponsor
- Nova Scotia Health
- Start
- Oct 2016
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of escitalopram and sertraline in major depressive disorder (MDD) and persistent depressive disorder (PDD) (2 arms), sponsored by Nova Scotia Health. Primary endpoint: Montgomery Asberg Depression Rating Scale. Started Oct 2016; status: recruiting.
02
Drugs
escitalopramsertraline
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on NCT02752542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752542.